Insmed Gets UK Marketing Authorization for Non-Cystic Fibrosis Bronchiectasis Treatment
MT Newswires Live
Yesterday
Insmed (INSM) unit Insmed Netherlands has received marketing authorization for brensocatib, or Brinsupri, from the UK's Medicines and Healthcare Products Regulatory Agency to treat non-cystic fibrosis bronchiectasis in patients aged at least 12 years old, the regulator said Monday.
The authorization covers patients who have experienced at least two flare-ups or worsening of symptoms in the last 12 months, the MHRA said.
NCFB is a chronic, long-term condition where the airways of the lungs are damaged, leading to a cough with mucus production.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.